TMO RSI Chart
Last 7 days
-0.2%
Last 30 days
-0.9%
Last 90 days
4.1%
Trailing 12 Months
7.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 42.5B | 0 | 0 | 0 |
2023 | 43.8B | 43.5B | 43.4B | 42.9B |
2022 | 41.1B | 42.8B | 44.2B | 44.9B |
2021 | 35.9B | 38.3B | 39.1B | 39.2B |
2020 | 25.6B | 26.2B | 28.5B | 32.2B |
2019 | 24.6B | 24.9B | 25.2B | 25.5B |
2018 | 22.0B | 23.1B | 23.9B | 24.4B |
2017 | 18.7B | 19.2B | 19.8B | 20.9B |
2016 | 17.3B | 17.6B | 18.0B | 18.3B |
2015 | 16.9B | 16.9B | 16.8B | 17.0B |
2014 | 13.8B | 14.9B | 15.9B | 16.9B |
2013 | 12.6B | 12.8B | 12.9B | 13.1B |
2012 | 11.9B | 12.2B | 12.3B | 12.5B |
2011 | 10.5B | 10.8B | 11.1B | 11.6B |
2010 | 10.3B | 10.4B | 10.5B | 10.4B |
2009 | 10.0B | 9.7B | 9.6B | 9.9B |
2008 | 0 | 9.9B | 10.1B | 10.3B |
2007 | 0 | 0 | 0 | 9.7B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 05, 2024 | pettiti gianluca | sold (taxes) | -67,249 | 572 | -117 | executive vice president |
May 05, 2024 | lowery frederick m. | sold (taxes) | -67,249 | 572 | -117 | executive vice president |
May 01, 2024 | casper marc n | acquired | 1,905,900 | 190 | 10,000 | chairman & ceo |
May 01, 2024 | casper marc n | sold | -5,737,360 | 573 | -10,000 | chairman & ceo |
Apr 30, 2024 | casper marc n | sold | -5,724,150 | 572 | -10,000 | chairman & ceo |
Apr 30, 2024 | casper marc n | acquired | 1,905,900 | 190 | 10,000 | chairman & ceo |
Apr 29, 2024 | casper marc n | sold | -5,759,380 | 575 | -10,000 | chairman & ceo |
Apr 29, 2024 | casper marc n | acquired | 1,905,900 | 190 | 10,000 | chairman & ceo |
Which funds bought or sold TMO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | KEATING INVESTMENT COUNSELORS INC | reduced | -28.29 | -730,642 | 2,670,660 | 0.86% |
May 07, 2024 | OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | added | 17.96 | 171,681 | 759,796 | 0.04% |
May 07, 2024 | NIXON PEABODY TRUST CO | added | 6.33 | 2,750,440 | 19,492,600 | 1.79% |
May 07, 2024 | NTV Asset Management LLC | unchanged | - | 215,444 | 2,483,510 | 0.38% |
May 07, 2024 | NEW SOUTH CAPITAL MANAGEMENT INC | reduced | -2.91 | 5,491,800 | 92,485,600 | 3.87% |
May 07, 2024 | ASSETMARK, INC | added | 10.73 | 3,154,310 | 17,998,100 | 0.06% |
May 07, 2024 | FORSTA AP-FONDEN | added | 10.48 | 9,348,420 | 53,918,900 | 0.46% |
May 07, 2024 | KCM INVESTMENT ADVISORS LLC | reduced | -2.78 | 362,625 | 5,978,990 | 0.22% |
May 07, 2024 | Swiss National Bank | reduced | -4.13 | 31,907,600 | 672,518,000 | 0.47% |
May 07, 2024 | Diversified Portfolios, Inc. | unchanged | - | 30,352 | 349,888 | 0.05% |
Unveiling Thermo Fisher Scientific Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Date Filed | Form Type | Document | |
---|---|---|---|
Peers (Alternatives to Thermo Fisher Scientific Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 184.8B | 23.7B | 41.98 | 7.79 | ||||
A | 41.9B | 6.7B | 33.87 | 6.22 | ||||
IDXX | 40.2B | 3.7B | 46.43 | 10.8 | ||||
DGX | 15.1B | 9.3B | 17.88 | 1.63 | ||||
CRL | 12.1B | 4.1B | 25.45 | 2.93 | ||||
MEDP | 12.0B | 2.0B | 38.39 | 6.11 | ||||
NTRA | 11.5B | 1.1B | -26.55 | 10.66 | ||||
EXAS | 11.0B | 2.5B | -45.65 | 4.33 | ||||
MID-CAP | ||||||||
NEOG | 2.6B | 929.2M | 1.7K | 2.81 | ||||
GH | 2.3B | 563.9M | -4.73 | 4.03 | ||||
SMALL-CAP | ||||||||
CDNA | 527.1M | 280.3M | -2.77 | 1.88 | ||||
ACRS | 86.9M | 31.1M | -1.13 | 2.79 | ||||
APDN | 63.3M | 9.0M | -8.76 | 7.04 | ||||
AWH | 36.8M | 9.2M | -2.2 | 4.02 | ||||
BIOC | 183.8K | 25.9M | -0.01 | 0.01 |
Thermo Fisher Scientific Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -5.0% | 10,345 | 10,886 | 10,574 | 10,687 | 10,710 | 11,450 | 10,677 | 10,970 | 11,818 | 10,702 | 9,330 | 9,273 | 9,906 | 10,550 | 8,521 | 6,917 | 6,230 | 6,829 | 6,272 | 6,316 | 6,125 |
Costs and Expenses | -3.9% | 8,682 | 9,032 | 8,710 | 9,109 | 9,147 | 9,589 | 8,967 | 8,969 | 8,997 | 8,164 | 7,052 | 7,110 | 6,857 | 7,479 | 6,095 | 5,526 | 5,324 | 5,597 | 5,326 | 4,820 | 5,205 |
S&GA Expenses | 2.4% | 2,183 | 2,132 | 2,049 | 2,145 | 2,119 | 2,299 | 2,208 | 2,209 | 2,277 | 2,278 | 2,004 | 1,899 | 1,826 | 2,077 | 1,592 | 1,710 | 1,551 | 1,512 | 1,539 | 1,565 | 1,528 |
R&D Expenses | 1.2% | 331 | 327 | 319 | 345 | 346 | 391 | 351 | 365 | 364 | 392 | 351 | 343 | 320 | 376 | 296 | 264 | 245 | 262 | 247 | 246 | 248 |
EBITDA Margin | 4.2% | 0.21* | 0.20* | 0.20* | 0.19* | 0.19* | 0.21* | 0.21* | 0.23* | 0.24* | 0.26* | 0.29* | 0.29* | 0.29* | 0.26* | 0.23* | 0.19* | 0.21* | 0.21* | 0.21* | - | - |
Interest Expenses | -6.9% | 363 | 390 | 359 | 326 | 300 | 269 | 173 | 148 | 136 | 161 | 128 | 122 | 125 | 146 | 144 | 137 | 126 | 142 | 164 | 181 | 189 |
Income Taxes | 111.3% | 281 | 133 | 53.00 | 52.00 | 46.00 | 173 | 31.00 | 198 | 301 | 203 | 271 | 219 | 416 | 394 | 319 | 97.00 | 40.00 | 36.00 | 62.00 | 274 | 2.00 |
Earnings Before Taxes | -8.7% | 1,589 | 1,740 | 1,765 | 1,430 | 1,363 | 1,777 | 1,601 | 1,917 | 2,540 | 1,862 | 2,177 | 2,049 | 2,753 | 2,897 | 2,252 | 1,253 | 828 | 1,040 | 822 | 1,393 | 817 |
EBT Margin | 4.5% | 0.15* | 0.15* | 0.15* | 0.14* | 0.15* | 0.17* | 0.18* | 0.20* | 0.21* | 0.23* | 0.25* | 0.26* | 0.26* | 0.22* | 0.19* | 0.15* | 0.16* | 0.16* | 0.16* | - | - |
Net Income | -17.1% | 1,331 | 1,606 | 1,695 | 1,362 | 1,292 | 1,574 | 1,498 | 1,668 | 2,220 | 1,659 | 1,903 | 1,829 | 2,337 | 2,500 | 1,933 | 1,156 | 788 | 1,002 | 760 | 1,119 | 815 |
Net Income Margin | 1.5% | 0.14* | 0.14* | 0.14* | 0.13* | 0.14* | 0.15* | 0.16* | 0.17* | 0.19* | 0.20* | 0.22* | 0.22* | 0.22* | 0.20* | 0.17* | 0.14* | 0.14* | 0.14* | 0.14* | - | - |
Free Cashflow | -72.8% | 904 | 3,318 | 2,082 | 1,256 | 271 | 2,937 | 1,390 | 1,022 | 1,562 | 1,626 | 2,126 | 1,687 | 1,350 | 2,753 | 2,342 | 1,617 | 103 | 1,624 | 901 | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -1.7% | 97,095 | 98,726 | 97,057 | 94,105 | 94,658 | 97,154 | 90,536 | 90,579 | 92,747 | 95,123 | 73,600 | 67,698 | 65,931 | 69,052 | 64,061 | 61,593 | 58,688 | 58,381 | 56,729 | 57,970 | 55,596 |
Current Assets | -3.9% | 23,640 | 24,589 | 23,092 | 19,995 | 20,209 | 25,229 | 19,299 | 18,100 | 18,776 | 20,113 | 24,724 | 19,260 | 17,685 | 21,957 | 18,234 | 15,775 | 12,738 | 11,893 | 10,514 | 11,223 | 9,939 |
Cash Equivalents | -31.7% | 5,519 | 8,077 | 6,151 | 3,133 | 3,482 | 8,524 | 2,934 | 1,905 | 2,779 | 4,491 | 12,048 | 7,035 | 5,603 | 10,336 | 7,570 | 5,837 | 3,010 | 2,422 | 1,305 | 2,314 | 1,128 |
Inventory | 0.9% | 5,133 | 5,088 | 5,404 | 5,655 | 5,664 | 5,634 | 5,722 | 5,668 | 5,483 | 5,051 | 4,906 | 4,625 | 4,342 | 4,029 | 3,829 | 3,648 | 3,454 | 3,370 | 3,308 | 3,209 | 3,124 |
Net PPE | -1.3% | 9,324 | 9,448 | 9,167 | 9,292 | 9,354 | 9,280 | 8,628 | 8,529 | 8,448 | 8,333 | 7,049 | 6,560 | 6,133 | 5,912 | 5,180 | 4,887 | 4,736 | 4,749 | 4,420 | 4,394 | 4,192 |
Goodwill | -0.4% | 43,843 | 44,020 | 43,583 | 43,273 | 43,140 | 41,196 | 40,488 | 41,066 | 41,721 | 41,924 | 26,909 | 26,904 | 26,823 | 26,041 | 25,782 | 25,700 | 25,614 | 25,714 | 25,624 | 25,757 | 25,236 |
Current Liabilities | -0.5% | 13,937 | 14,012 | 14,158 | 14,112 | 15,884 | 17,010 | 11,118 | 10,997 | 12,070 | 13,436 | 7,753 | 6,925 | 6,995 | 10,304 | 6,228 | 6,013 | 5,500 | 6,197 | 5,844 | 7,509 | 5,898 |
Long Term Debt | -0.5% | 31,157 | 31,308 | 30,489 | 29,194 | 29,135 | 28,909 | 28,150 | 29,250 | 31,389 | 32,333 | 21,688 | 18,773 | 18,641 | 19,107 | 21,091 | 20,638 | 19,231 | 17,076 | 16,392 | 16,663 | 16,812 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | 18,773 | 18,641 | 19,107 | 21,091 | 20,638 | 19,231 | 17,076 | 16,392 | - | - |
Shareholder's Equity | -2.6% | 45,504 | 46,735 | 45,328 | 43,802 | 42,310 | 43,978 | 43,608 | 42,354 | 41,018 | 40,855 | 38,757 | 36,901 | 35,068 | 34,517 | 31,824 | 29,875 | 28,559 | 29,684 | 29,355 | 28,729 | 27,693 |
Retained Earnings | 2.5% | 48,542 | 47,364 | 45,869 | 44,289 | 43,064 | 41,910 | 40,452 | 39,074 | 37,528 | 35,431 | 33,876 | 32,076 | 30,350 | 28,116 | 25,705 | 23,860 | 22,791 | 22,092 | 21,165 | 20,482 | 19,439 |
Additional Paid-In Capital | 1.1% | 17,482 | 17,286 | 17,165 | 17,030 | 16,889 | 16,743 | 16,596 | 16,467 | 16,292 | 16,174 | 15,960 | 15,826 | 15,684 | 15,579 | 15,467 | 15,334 | 15,186 | 15,064 | 14,964 | 14,887 | 14,771 |
Shares Outstanding | -1.1% | 382 | 386 | 386 | 386 | 386 | 392 | 392 | 392 | 392 | 394 | 394 | 393 | 394 | 396 | 396 | 395 | 397 | 400 | 400 | - | - |
Minority Interest | -9.1% | -12.00 | -11.00 | 18.00 | 50.00 | 53.00 | 54.00 | 59.00 | 61.00 | 62.00 | 62.00 | - | - | - | 10.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 201,177 | - | - | - | 214,582 | - | - | - | 201,672 | - | - | - | 138,640 | - | - | - | 117,442 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -66.4% | 1,251 | 3,723 | 2,414 | 1,540 | 729 | 3,487 | 1,937 | 1,528 | 2,202 | 2,457 | 2,650 | 2,227 | 1,978 | 3,339 | 2,708 | 1,886 | 356 | 1,913 | 1,117 | 1,294 | 649 |
Share Based Compensation | 14.8% | 70.00 | 61.00 | 67.00 | 74.00 | 76.00 | 75.00 | 77.00 | 77.00 | 78.00 | 77.00 | 51.00 | 51.00 | 51.00 | 51.00 | 52.00 | 47.00 | 46.00 | 43.00 | 42.00 | 52.00 | 44.00 |
Cashflow From Investing | -439.9% | -2,030 | -376 | -1,181 | -443 | -3,142 | -525 | -545 | -419 | -670 | -18,692 | -616 | -626 | -1,998 | -626 | -365 | -259 | -260 | -339 | -198 | -769 | -181 |
Cashflow From Financing | -27.5% | -1,821 | -1,428 | 1,855 | -1,456 | -2,593 | 2,391 | -151 | -1,905 | -3,145 | 8,467 | 3,040 | -76.00 | -4,850 | -49.00 | -791 | 1,180 | 619 | -514 | -1,869 | 690 | -1,425 |
Dividend Payments | -0.7% | 135 | 136 | 135 | 135 | 117 | 117 | 118 | 117 | 103 | 103 | 102 | 103 | 87.00 | 87.00 | 87.00 | 87.00 | 76.00 | 76.00 | 77.00 | 76.00 | 68.00 |
Buy Backs | - | 3,000 | - | - | - | 3,000 | 1,000 | - | - | 2,000 | - | - | - | 2,000 | - | - | - | 1,500 | 750 | - | - | 750 |
Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 30, 2024 | Apr. 01, 2023 | |
Revenues | ||
Revenues | $ 10,345 | $ 10,710 |
Costs and operating expenses: | ||
Selling, general and administrative expenses | 2,183 | 2,119 |
Research and development expenses | 331 | 346 |
Restructuring and other costs | 29 | 112 |
Total costs and operating expenses | 8,682 | 9,147 |
Operating income | 1,663 | 1,563 |
Interest income | 279 | 146 |
Interest expense | (363) | (300) |
Other income/(expense) | 10 | (46) |
Income before income taxes | 1,589 | 1,363 |
Provision for income taxes | (281) | (46) |
Equity in earnings/(losses) of unconsolidated entities | 23 | (25) |
Net income | 1,331 | 1,292 |
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest | 4 | 3 |
Net income attributable to Thermo Fisher Scientific Inc. | $ 1,328 | $ 1,289 |
Earnings per share attributable to Thermo Fisher Scientific Inc. | ||
Basic (in dollars per share) | $ 3.47 | $ 3.34 |
Diluted (in dollars per share) | $ 3.46 | $ 3.32 |
Weighted average shares | ||
Basic (in shares) | 382 | 386 |
Diluted (in shares) | 384 | 388 |
Product revenues | ||
Revenues | ||
Revenues | $ 5,955 | $ 6,404 |
Costs and operating expenses: | ||
Cost of revenues | 2,939 | 3,337 |
Service revenues | ||
Revenues | ||
Revenues | 4,390 | 4,306 |
Costs and operating expenses: | ||
Cost of revenues | $ 3,201 | $ 3,233 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Mar. 30, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,499 | $ 8,077 |
Short-term investments | 1,751 | 3 |
Accounts receivable, less allowances of $197 and $193 | 7,931 | 8,221 |
Inventories | 5,133 | 5,088 |
Contract assets, net | 1,422 | 1,443 |
Other current assets | 1,904 | 1,757 |
Total current assets | 23,640 | 24,589 |
Property, plant and equipment, net | 9,324 | 9,448 |
Acquisition-related intangible assets, net | 16,048 | 16,670 |
Other assets | 4,241 | 3,999 |
Goodwill | 43,843 | 44,020 |
Total assets | 97,095 | 98,726 |
Current liabilities: | ||
Short-term obligations and current maturities of long-term obligations | 4,451 | 3,609 |
Accounts payable | 2,555 | 2,872 |
Accrued payroll and employee benefits | 1,314 | 1,596 |
Contract liabilities | 2,632 | 2,689 |
Other accrued expenses | 2,985 | 3,246 |
Total current liabilities | 13,937 | 14,012 |
Deferred income taxes | 1,811 | 1,922 |
Other long-term liabilities | 4,567 | 4,642 |
Long-term obligations | 31,157 | 31,308 |
Redeemable noncontrolling interest | 119 | 118 |
Thermo Fisher Scientific Inc. shareholders’ equity: | ||
Preferred stock, $100 par value, 50,000 shares authorized; none issued | 0 | 0 |
Common stock, $1 par value, 1,200,000,000 shares authorized; 442,822,699 and 442,188,634 shares issued | 443 | 442 |
Capital in excess of par value | 17,482 | 17,286 |
Retained earnings | 48,542 | 47,364 |
Treasury stock at cost, 61,106,376 and 55,541,290 shares | (18,186) | (15,133) |
Accumulated other comprehensive income/(loss) | (2,764) | (3,224) |
Total Thermo Fisher Scientific Inc. shareholders’ equity | 45,516 | 46,735 |
Noncontrolling interests | (12) | (11) |
Total equity | 45,504 | 46,724 |
Total liabilities, redeemable noncontrolling interest and equity | $ 97,095 | $ 98,726 |